Stoke Therapeutics, Inc. (STOK)
NASDAQ: STOK · Real-Time Price · USD
31.03
+1.69 (5.76%)
May 26, 2026, 4:00 PM EDT - Market closed
Stoke Therapeutics Stock Forecast
Stock Price Forecast
According to 12 analysts polled by S&P Global, Stoke Therapeutics stock has a consensus rating of "Strong Buy" and an average price target of $45.1. The average 1-year stock price forecast is 45.34% higher than the current stock price, while the lowest is $35 (+12.79%) and the highest is $60 (+93.36%).
Price Target: $45.1 (+45.34%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Stoke Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 | May '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 9 | 9 | 11 | 11 | 11 | 11 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 10 | 10 | 12 | 12 | 12 | 12 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| BTIG | BTIG | Buy Maintains $39 | Buy | Maintains | $39 | +25.68% | May 11, 2026 |
| H.C. Wainwright | H.C. Wainwright | Buy Maintains $50 | Buy | Maintains | $50 | +61.13% | May 8, 2026 |
| Canaccord Genuity | Canaccord Genuity | Buy Maintains $60 | Buy | Maintains | $60 | +93.36% | May 8, 2026 |
| Wedbush | Wedbush | Buy Maintains $38 | Buy | Maintains | $38 | +22.46% | May 8, 2026 |
| Needham | Needham | Buy Maintains $40 | Buy | Maintains | $40 | +28.91% | May 8, 2026 |
Financial Forecast
Revenue This Year
32.61M
from 184.42M
Decreased by -82.32%
Revenue Next Year
52.28M
from 32.61M
Increased by 60.32%
EPS This Year
-3.41
from -0.12
EPS Next Year
-3.23
from -3.41
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 61.6M | 110.3M | ||||||
| Avg | 32.6M | 52.3M | ||||||
| Low | 15.7M | 19.6M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | -66.6% | 238.1% | ||||||
| Avg | -82.3% | 60.3% | ||||||
| Low | -91.5% | -39.9% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | -3.22 | -2.15 | ||||||
| Avg | -3.41 | -3.23 | ||||||
| Low | -3.79 | -3.71 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | - | - | ||||||
| Avg | - | - | ||||||
| Low | - | - |
Sources: Price targets and consensus ratings provided by S&P Global Market Intelligence. Historical ratings and analyst data provided by TipRanks. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data sources.